Brief: NMPA Accepts Application By United Laboratories International's Unit For Marketing A Drug
14/10/2024 12:15
Oct 14 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* ON OCT 12, APPLICATION BY UNIT FOR MARKETING OF INSULIN
DEGLUDEC
INJECTION 3ML: 300U (DISPOSABLE PEN-TYPE)) ACCEPTED BY NMPA
Further company coverage: 3933.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million